Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

• ClinicalTrials.gov Identifier: NCT05144347
• Recruitment Status: Recruiting
• First Posted: December 3, 2021
• Last Update Posted: September 2, 2022
• Sponsor: Exelixis
• Information provided by (Responsible Party): Exelixis

Study Description

Brief Summary:

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.

Condition or disease	Intervention/treatment	Phase
Non-Hodgkin's Lymphoma (NHL); Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL); Mantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	Drug: XL114	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 144 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Dose-escalation followed by Cohort-expansion in NHL-specific expansion cohorts
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
• Actual Study Start Date: April 12, 2022
• Estimated Primary Completion Date: December 11, 2025
• Estimated Study Completion Date: December 11, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: XL114 Dose-Escalation Cohorts; Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.	Drug: XL114; Tablets of XL114
Experimental: XL114 Expansion Cohorts; The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma [ABC-DLBCL] (Cohort B), mantle cell lymphoma [MCL] (Cohort C), chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).	Drug: XL114; Tablets of XL114

Outcome Measures

Primary Outcome Measures :

1. Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114 [ Time Frame: 4-6 months ]
   To determine the RD and/or MTD of XL114 administered orally in subjects with NHL
2. Cohort-Expansion Stage: Objective Response Rate (ORR) [ Time Frame: 4-6 months ]
   To evaluate preliminary efficacy of XL114 by estimating the ORR based on lymphoma-specific response criteria as assessed by the Investigator

Secondary Outcome Measures :

1. Safety of XL114, as evaluated by Adverse Events (AEs) [ Time Frame: 4-6 months ]
   To evaluate the safety of XL114 through the evaluation of incidence and severity of treatment emergent nonserious adverse events (AEs) and serious adverse events (SAEs)at each dose level and their relationship to study drug treatment.
2. Tolerability of XL114, as evaluated by Dose Intensity, Dose Modifications, and Study Discontinuation due to AEs [ Time Frame: 4-6 months ]
   To evaluate the tolerability of XL114 through the evaluation of dose intensity, dose modifications and study treatment discontinuation due to AEs related to XL114.
3. Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax) [ Time Frame: 4-6 months ]
   To evaluate the Tmax of XL114.
4. Dose-Escalation Stage: Maximum Plasma Concentration (Cmax) [ Time Frame: 4-6 months ]
   To evaluate the Cmax of XL114.
5. Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24) [ Time Frame: 4-6 months ]
   To evaluate the AUC 0-24 of XL114.
6. Dose-Escalation Stage: Terminal Half-Life [ Time Frame: 4-6 months ]
   To evaluate the terminal half-life of XL114.
7. Dose-Escalation Stage: Apparent Clearance (CL/F) [ Time Frame: 4-6 months ]
   To evaluate the CL/F of XL114.
8. Cohort-Expansion Stage: Antitumor Activity of XL114 (Objective Response Rate [ORR]) [ Time Frame: 4-6 months ]
   To evaluate the antitumor activity of XL114 as measured by ORR based on lymphoma-specific response criteria as assessed by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.
9. Cohort-Expansion Stage: Antitumor Activity of XL114 (Duration of Response [DOR]) [ Time Frame: 4-6 months ]
   To evaluate the antitumor activity of XL114 as measured by DOR based on lymphoma-specific response criteria as assessed by the Investigator or by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.
10. Cohort-Expansion Stage: Antitumor Activity of XL114 (Progression Free Survival [PFS]) [ Time Frame: 4-6 months ]
    To evaluate the antitumor activity of XL114 as measured by PFS based on lymphoma-specific response criteria as assessed by the Investigator or by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.
11. Cohort-Expansion Stage: Overall Survival (OS) of XL114 [ Time Frame: 4-6 months ]
    To evaluate duration of overall survival (OS)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Dose-Escalation Stage (Cohort A) and Cohort-Expansion Stage (B-E): The subject has received standard life-prolonging therapies or are not qualified to receive such therapies.
• Dose-Escalation Stage (Cohort A): Subjects with histologically documented diagnosis of B-cell or T-cell Non-Hodgkin's Lymphoma as defined by the World Health Organization (WHO) classification. Note: Refer to exclusion criteria for lymphoma subtypes which are excluded from study participation.
• Cohort-Expansion Stage Cohort B (ABC-DLBCL subtype): Subjects with histologically documented activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) subtype. Note: De novo or transformed diffuse large B-cell lymphoma (DLBCL) from previously diagnosed indolent lymphoma (eg, follicular lymphoma) is allowed.
• Cohort-Expansion Stage Cohort C (MCL): Subjects with histologically documented MCL with monoclonal B-cells that show a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1.
• Cohort-Expansion Stage Cohort D (CLL/SLL): Subjects with histologically documented CLL/SLL per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.
• Cohort-Expansion Stage Cohort E, Biomarker Cohort (ABC-DLBCL, MCL, and SLL): Subjects with ABC-DLBCL, MCL, and SLL that fulfill the subject disease characteristics criteria as described for Cohorts B, C, or D.
• Cohort-Expansion Stage: Subjects with ABC-DLBCL, MCL, and SLL must have measurable disease by revised criteria for response assessment of lymphoma.
• Cohort-Expansion Stages: Must have archival tumor tissue available, which was collected up to 2 years prior to consent for this study. If archival tumor tissue is not available, a fresh tumor biopsy may be obtained (if safe to acquire) up to 60 days prior to first dose.
• Biomarker Cohort: Subjects must provide a fresh tumor biopsy up to 60 days prior to first dose, at week 2, day 1 (W2D1) after initiation of XL114, and at disease progression. Note: The tumor tissue requirement in the Expansion and Biomarker cohorts doesn't apply for subjects with CLL.
• Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 [CTCAE v5]) from AEs, unless AEs are clinically nonsignificant or stable.
• Left ventricular ejection fraction (LVEF) > 50% as determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan per local standard.
• Age 18 years or older on the day of consent.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1
• Adequate organ and marrow function
• Sexually active fertile subjects and their partners must agree to highly effective methods of contraception.
• Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

• Receipt of prior therapies as defined in the protocol
• The following lymphoma types/manifestations are not eligible for this study: Burkitt's lymphoma (BL), Burkitt-like lymphoma (BLL), lymphoblastic lymphoma/leukemia (LBL), post-transplant lymphoproliferative disease (PTLD), primary mediastinal (thymic) large B-cell lymphoma (PMBL), lymphomas involving the central nervous system (CNS) or meninges
• History of autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).
• History of solid organ or allogeneic hematopoietic stem cell transplantation.
• Concomitant anticoagulation with the oral anticoagulants apixaban, betrixaban, rivaroxaban, and dabigatran.
• Use of a strong inhibitor or inducer of cytochrome P450 3A4 (CYP3A4) within 5 half-lives or 4 weeks prior to first dose of study treatment, whichever is shorter.
• Uncontrolled, significant intercurrent or recent illness
• Major surgery (eg, GI surgery) within 3 weeks before first dose of study treatment.
• Corrected QT interval calculated by the Fridericia formula (QTcF) > 470 ms per electrocardiogram (ECG).
• Pregnant or lactating females.
• Inability to swallow XL114 tablets.
• Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy

Contacts and Locations

Contacts

Contact: Exelixis Clinical Trials; 1-888-EXELIXIS (888-393-5494); druginfo@exelixis.com

Contact: Backup or International; 650-837-7400

Locations

United States, Arizona

Exelixis Clinical Site #3; Recruiting

Tucson, Arizona, United States, 85719

United States, Indiana

Exelixis Clinical Site #1; Recruiting

Indianapolis, Indiana, United States, 46250

United States, Washington

Exelixis Clinical Site #2; Recruiting

Spokane, Washington, United States, 99208

Sponsors and Collaborators

Exelixis

More Information

• Responsible Party: Exelixis
• ClinicalTrials.gov Identifier: NCT05144347
• Other Study ID Numbers: XL114-101
• First Posted: December 3, 2021
• Last Update Posted: September 2, 2022
• Last Verified: September 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Exelixis:

Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1); B-cell Malignancies; Fatty Acid Binding Protein 5 (FABP-5)

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, Lymphoid; Leukemia; Lymphoma, B-Cell; Leukemia, B-Cell